Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Initiates 1-for-15 Reverse Stock Split

NEW YORK (GenomeWeb) – CombiMatrix announced today that its board has approved a 1-for-15 reverse split of its common stock.

The reverse split was authorized so that the molecular diagnostics company could regain compliance with the Nasdaq's minimum bid price listing maintenance requirements, CombiMatrix said. The company was warned in December that it could face delisting from the Nasdaq for failing to meet the stock exchange's $1 minimum bid price. It was given 180 calendar days in which to regain compliance.

The reverse split will also increase the number of shares of common stock available for the company to issue. No fractional shares will be issued, and any shareholders who would have been entitled to a fractional share of the new common stock will now receive a cash payment instead, the company added. Proportional adjustments will also be made to the company's 2006 Stock Incentive Plan reserve and to its outstanding stock options, restricted stock unit awards, Series E Preferred Stock, and warrants. 

The reverse stock split will become effective on Jan. 29, and will be effective for trading purposes on Feb. 1. 

CombiMatrix's shares were down 6 percent to $.43 in morning trade.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.